ArticleInternational journal of endocrine oncology2016
The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications.
Article in International journal of endocrine oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- ShadoNet: a cell detection and classification framework for Ki-67 pathology images.Bioinformatics (Oxford, England) · 2026Article
- Integrated Pathologic, Genomic, and Transcriptomic Analysis of Renal Neuroendocrine Tumors Reveals Neuroendocrine Transcriptional Programs and Associated Gastrointestinal-Type Epithelium in a Subset of Cases.Endocrine pathology · 2026Article
- Review
- Machine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers.Current oncology (Toronto, Ont.) · 2026Review
- Neuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives.Cureus · 2026Review
- Research productivity and trends in gastric neuroendocrine neoplasms in the early 21st century: a bibliometric and visualized analysis.Discover oncology · 2025Article
- Review
- Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.Frontiers in nuclear medicine · 2025Review
- Primary Well-Differentiated Neuroendocrine Tumor/Carcinoid of the Prostate: Case Report and Review of Literature.International journal of surgical pathology · 2024Review
- Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy.Annals of surgical oncology · 2024Article
- [Search for new immunohistochemical and circulating markers of insulinoma].Problemy endokrinologii · 2024Article
- Gallbladder carcinoid in a cat.The Canadian veterinary journal = La revue veterinaire canadienne · 2024Article
- A relook at gastroenteropancreatic neuroendocrine tumours as per 2019 WHO classification-A tertiary centre experience.Irish journal of medical science · 2023Article
- Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors.Langenbeck's archives of surgery · 2023Article
- Development and validation of a survival prediction model and risk stratification for pancreatic neuroendocrine neoplasms.Journal of endocrinological investigation · 2023Article
- Neuroendocrine Neoplasms of the Gastrointestinal Tract versus Neuroendocrine Neoplasms of the Gynaecological Tract-Comparison of the Risk Factors and Non-Surgical Treatment Efficacy.International journal of molecular sciences · 2023Review
- Article
- What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?BMC cancer · 2023Article
- Rectal neuroendocrine neoplasms: what the radiologists should know.Abdominal radiology (New York) · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The understanding of neuroendocrine neoplasms has evolved significantly since their initial descriptions in the 1800s to early 1900s. In the gastroenteropancreatic system, this group of malignant tumors is subdivided into well and poorly differentiated neuroendocrine neoplasms based on morphologic, proliferative and biologic differences. However, it has become increasingly apparent that well-differentiated neuroendocrine tumors are not a homogeneous group. Attempting to better predict outcome of these tumors has been the motivation behind numerous proposed classification systems, the evolution of which culminated with the currently used system, the ENETS/WHO classification. Herein, we review the genesis of this classification system and some of its shortcomings. In addition, we discuss some of the most recent proposals that suggest modifications to the current system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.